A clinical trial assessing dovramilast for the treatment of leprosy type 2 reaction
Latest Information Update: 09 May 2025
At a glance
- Drugs Dovramilast (Primary)
- Indications Leprosy
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2025 Status changed from planning to not yet recruiting as per Medicines Development for Global Health (MDGH) media release
- 30 Apr 2025 According to Medicines Development for Global Health (MDGH) media release, the USFDA cleared the companys Investigational New Drug (IND) Application for dovramilast and its global Phase 2 clinical trial may proceed in the United States to assess dovramilast in people with acute or recurrent leprosy type 2 reaction. The study is expected to begin by the end of Q3 2025, with sites in the United States, Philippines, Indonesia, Cote dvoire, Benin and Madagascar.
- 06 Mar 2025 New trial record